JNP Insider Trading Activity and SEC Form 4 Filings
JNP insider trading summary
No open-market insider purchases or sales of Juniper Pharmaceuticals Inc (JNP) have been reported on SEC Form 4 in the past 12 months.
Latest JNP insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Mar 17, 2017 | James A Geraghty | Director | Buy | $10K (2,000 @ $4.82) |
| Sep 13, 2016 | James A Geraghty | Director | Buy | $12K (2,000 @ $5.96) |
| Aug 31, 2016 | George Elston | Chief Financial Officer | Buy | $6K (1,000 @ $5.50) |
| Aug 26, 2016 | C Ann Merrifield | Director | Buy | $11K (2,000 @ $5.63) |
| Aug 25, 2016 | Alicia Secor | President and CEO | Buy | $29K (5,000 @ $5.75) |
| Aug 23, 2016 | James A Geraghty | Director | Buy | $18K (2,937 @ $6.03) |
| Aug 23, 2016 | Frank M Armstrong | Director | Buy | $10K (1,623 @ $6.16) |
| Aug 22, 2016 | James A Geraghty | Director | Buy | $24K (4,063 @ $5.90) |
| Dec 4, 2015 | C Ann Merrifield | Director | Buy | $19K (1,600 @ $12.14) |
| Nov 19, 2015 | Nikin Patel | COO | Buy | $51K (4,300 @ $11.88) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.